Literature DB >> 32810901

Comparison of the effects of losartan, captopril, angiotensin II type 2 receptor agonist compound 21, and MAS receptor agonist AVE 0991 on myocardial ischemia-reperfusion necrosis in rats.

Onural Ozhan1, Hakan Parlakpinar1, Ahmet Acet1.   

Abstract

Myocardial ischemia may occur as a result of pathophysiological and therapeutical applications such as atherosclerosis, thromboembolism, percutaneous transluminal coronary angioplasty, coronary artery bypass, and transplantation. In this study, we aimed to compare the effects of angiotensin (Ang) II type 2 (AT2 ) selective receptor agonist Compound 21 (C21), MAS receptor agonist AVE 0991, Ang II type 1 (AT1 ) selective receptor blocker losartan, and Ang-converting enzyme inhibitor captopril on haemodynamic parameters and infarct size on myocardial ischemia/reperfusion (MI/R)-induced necrosis in rats. To induce necrosis in the heart of rats, reperfusion for 2 h following ischemia for 30 min to the descending branch of the left main coronary artery was achieved. C21 (0.03 mg/kg), AVE 0991 (576 μg/kg), losartan (2 mg/kg), and captopril (3 mg/kg) were administered as an intravenous infusion at 10 min before and throughout the ischemia. Then, the infarct size and risk area were calculated from the heart. The percentage of myocardial infarct size to area at risk ratio (%IS/AR) of groups was Control (MI/R) group: 48.9 ± 8.8%; C21 group: 31.1 ± 7.8%; AVE 0991 group: 29.9 ± 4.8%; C21 + AVE 0991 group: 28.2 ± 3.3%; Losartan + AVE 0991 group: 30.8 ± 5.8%; Captopril + AVE 0991 group: 31.7 ± 7.7%. %IS/AR of the drug-treated groups decreased significantly when compared to the MI/R group (P < 0.05). Our results indicate that the importance of AT1 , AT2 , and MAS receptors in the MI/R injury. Inhibition of Ang II formation by captopril, blockade of AT1 receptor with losartan, and stimulation of AT2 receptor with C21 and MAS receptor with AVE 0991 showed beneficial effects by reducing infarct size.
© 2020 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  AVE 0991; captopril; compound 21; losartan; myocardial ischemia-reperfusion injury

Mesh:

Substances:

Year:  2020        PMID: 32810901     DOI: 10.1111/fcp.12599

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  2 in total

1.  Strengthening CoViD-19 therapy via combinations of RAS modulators.

Authors:  Veselina V Uzunova; Angel Todev; Jacqueline Zarkos; Daniel Addai; Julian Ananiev; Pavel Rashev; Radostina Alexandrova; Anna Tolekova
Journal:  Med Hypotheses       Date:  2021-03-25       Impact factor: 1.538

Review 2.  Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19.

Authors:  Tomas Rajtik; Peter Galis; Linda Bartosova; Ludovit Paulis; Eva Goncalvesova; Jan Klimas
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.